Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma

PHASE4CompletedINTERVENTIONAL
Enrollment

259

Participants

Timeline

Start Date

October 1, 2015

Primary Completion Date

February 4, 2016

Study Completion Date

February 4, 2016

Conditions
Asthma
Interventions
DRUG

Placebo ELLIPTA inhaler

The ELLIPTA Dry Powder Inhaler (DPI) is a molded plastic two-sided inhaler that can hold two individual blister strips. Each strip will contain either lactose or a blend of lactose and magnesium stearate. Subjects will receive 1 inhalation once-daily until visit 2.

OTHER

Questionnaire

ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.

Trial Locations (15)

21236

GSK Investigational Site, Baltimore

28277

GSK Investigational Site, Charlotte

29379

GSK Investigational Site, Union

33173

GSK Investigational Site, Miami

33180

GSK Investigational Site, Aventura

36608

GSK Investigational Site, Mobile

55402

GSK Investigational Site, Minneapolis

55441

GSK Investigational Site, Plymouth

70584

GSK Investigational Site, Sunset

73120

GSK Investigational Site, Oklahoma City

76712

GSK Investigational Site, Waco

78229

GSK Investigational Site, San Antonio

92647

GSK Investigational Site, Huntington Beach

97504

GSK Investigational Site, Medford

02747

GSK Investigational Site, North Dartmouth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02586506 - Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma | Biotech Hunter | Biotech Hunter